Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients

Fujiko Mitsumoto-Kaseida, Masayuki Murata, Koji Takayama, Kazuhiro Toyoda, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi

研究成果: ジャーナルへの寄稿記事

抄録

Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) naïve HIV infected patients. OBI was defined as the presence of serum HBV DNA but without detectable HBsAg. Of the 147 ART naïve HIV infected patients, OBI was detected in 9 (6.1%) patients; 2 (4.3%) of 47 with both anti-HBs and anti-HBc positive, 6 (27.3%) of 22 with anti-HBc alone, and 1 (2.0%) of 50 with both anti-HBs and anti-HBc negative. The mean HBV DNA level was low at 28.7 ± 18.2 IU/mL. The proportion of OBI patients with anti-HBc alone was significantly higher than that of non-OBI patients (66.7% vs 14.5%, P = 0.001). In addition, the prevalence of AIDS (acquired immunodeficiency syndrome)-defining illnesses in the OBI group was significantly higher than in the non-OBI group (77.8% vs 35.5%, P = 0.001). No significant difference was found in the CD4 count or alanine aminotransferase levels of these two groups. This is the first study to reveal the prevalence and clinical features of OBI in Japanese HIV-infected patients. The persistence of anti-HBc alone and AIDS-defining illnesses were associated with the occurrence of OBI in these patients.

元の言語英語
ページ(範囲)28-32
ページ数5
ジャーナルJournal of Infection and Chemotherapy
26
発行部数1
DOI
出版物ステータス出版済み - 1 2020

Fingerprint

Virus Diseases
Hepatitis B virus
HIV
Hepatitis B Surface Antigens
DNA
Acquired Immunodeficiency Syndrome
CD4 Lymphocyte Count
Alanine Transaminase
HIV Infections
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

これを引用

Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients. / Mitsumoto-Kaseida, Fujiko; Murata, Masayuki; Takayama, Koji; Toyoda, Kazuhiro; Ogawa, Eiichi; Furusyo, Norihiro; Hayashi, Jun.

:: Journal of Infection and Chemotherapy, 巻 26, 番号 1, 01.2020, p. 28-32.

研究成果: ジャーナルへの寄稿記事

@article{bea5658b801e4fb88bff3b01f6d7fd0f,
title = "Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients",
abstract = "Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) na{\"i}ve HIV infected patients. OBI was defined as the presence of serum HBV DNA but without detectable HBsAg. Of the 147 ART na{\"i}ve HIV infected patients, OBI was detected in 9 (6.1{\%}) patients; 2 (4.3{\%}) of 47 with both anti-HBs and anti-HBc positive, 6 (27.3{\%}) of 22 with anti-HBc alone, and 1 (2.0{\%}) of 50 with both anti-HBs and anti-HBc negative. The mean HBV DNA level was low at 28.7 ± 18.2 IU/mL. The proportion of OBI patients with anti-HBc alone was significantly higher than that of non-OBI patients (66.7{\%} vs 14.5{\%}, P = 0.001). In addition, the prevalence of AIDS (acquired immunodeficiency syndrome)-defining illnesses in the OBI group was significantly higher than in the non-OBI group (77.8{\%} vs 35.5{\%}, P = 0.001). No significant difference was found in the CD4 count or alanine aminotransferase levels of these two groups. This is the first study to reveal the prevalence and clinical features of OBI in Japanese HIV-infected patients. The persistence of anti-HBc alone and AIDS-defining illnesses were associated with the occurrence of OBI in these patients.",
author = "Fujiko Mitsumoto-Kaseida and Masayuki Murata and Koji Takayama and Kazuhiro Toyoda and Eiichi Ogawa and Norihiro Furusyo and Jun Hayashi",
year = "2020",
month = "1",
doi = "10.1016/j.jiac.2019.06.003",
language = "English",
volume = "26",
pages = "28--32",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients

AU - Mitsumoto-Kaseida, Fujiko

AU - Murata, Masayuki

AU - Takayama, Koji

AU - Toyoda, Kazuhiro

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Hayashi, Jun

PY - 2020/1

Y1 - 2020/1

N2 - Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) naïve HIV infected patients. OBI was defined as the presence of serum HBV DNA but without detectable HBsAg. Of the 147 ART naïve HIV infected patients, OBI was detected in 9 (6.1%) patients; 2 (4.3%) of 47 with both anti-HBs and anti-HBc positive, 6 (27.3%) of 22 with anti-HBc alone, and 1 (2.0%) of 50 with both anti-HBs and anti-HBc negative. The mean HBV DNA level was low at 28.7 ± 18.2 IU/mL. The proportion of OBI patients with anti-HBc alone was significantly higher than that of non-OBI patients (66.7% vs 14.5%, P = 0.001). In addition, the prevalence of AIDS (acquired immunodeficiency syndrome)-defining illnesses in the OBI group was significantly higher than in the non-OBI group (77.8% vs 35.5%, P = 0.001). No significant difference was found in the CD4 count or alanine aminotransferase levels of these two groups. This is the first study to reveal the prevalence and clinical features of OBI in Japanese HIV-infected patients. The persistence of anti-HBc alone and AIDS-defining illnesses were associated with the occurrence of OBI in these patients.

AB - Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) naïve HIV infected patients. OBI was defined as the presence of serum HBV DNA but without detectable HBsAg. Of the 147 ART naïve HIV infected patients, OBI was detected in 9 (6.1%) patients; 2 (4.3%) of 47 with both anti-HBs and anti-HBc positive, 6 (27.3%) of 22 with anti-HBc alone, and 1 (2.0%) of 50 with both anti-HBs and anti-HBc negative. The mean HBV DNA level was low at 28.7 ± 18.2 IU/mL. The proportion of OBI patients with anti-HBc alone was significantly higher than that of non-OBI patients (66.7% vs 14.5%, P = 0.001). In addition, the prevalence of AIDS (acquired immunodeficiency syndrome)-defining illnesses in the OBI group was significantly higher than in the non-OBI group (77.8% vs 35.5%, P = 0.001). No significant difference was found in the CD4 count or alanine aminotransferase levels of these two groups. This is the first study to reveal the prevalence and clinical features of OBI in Japanese HIV-infected patients. The persistence of anti-HBc alone and AIDS-defining illnesses were associated with the occurrence of OBI in these patients.

UR - http://www.scopus.com/inward/record.url?scp=85068229936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068229936&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2019.06.003

DO - 10.1016/j.jiac.2019.06.003

M3 - Article

C2 - 31279522

AN - SCOPUS:85068229936

VL - 26

SP - 28

EP - 32

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 1

ER -